Collectively, these observations suggest that D2R agonist cabergoline likely reduces tumour angiogenesis by decreasing proliferation and migration of tumour microenvironment resident endothelial cells, in addition to D2R agonist-mediated stimulation of tumour-associated endothelial cell apoptosis. Here, DRD2 is linked to neoplasm.